Liraglutide vs Trulicity (Dulaglutide): Real-World Evidence Comparison

What Are Liraglutide and Dulaglutide?

Liraglutide and dulaglutide both activate the glucagon-like peptide-1 (GLP-1) receptor, slowing gastric emptying, suppressing glucagon, and stimulating glucose-dependent insulin release. They share a mechanism but diverge on molecular half-life, which drives the biggest practical difference: liraglutide must be injected every day, while dulaglutide's albumin-fusion extends its half-life to roughly 5 days, allowing once-weekly dosing.

Liraglutide at a Glance

Liraglutide was first approved by the FDA in January 2010 under the brand name Victoza for type 2 diabetes. A higher-dose formulation, Saxenda (3.0 mg daily), was approved in December 2014 specifically for chronic weight management in adults with a BMI of 30 or above, or BMI <27 with at least one weight-related comorbidity. Generic liraglutide became available in the US market beginning in 2024, which has meaningfully changed the cost calculus for many patients. The FDA approval history is searchable at the FDA's Drugs@FDA database.

Dulaglutide (Trulicity) at a Glance

Dulaglutide was FDA-approved in September 2014 for type 2 diabetes. Its single-use, needle-hidden autoinjector was specifically designed to reduce injection anxiety, and real-world satisfaction surveys consistently show high device preference scores among injection-naive patients. Dulaglutide is not FDA-approved for weight management as a standalone indication, though it does produce modest weight loss in most users. It is also approved to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors, based on the REWIND trial. Full prescribing information is available via FDA.

Head-to-Head Glycemic Efficacy

Both drugs produce clinically meaningful HbA1c reductions, and no large randomized head-to-head trial has consistently declared one superior in glucose lowering. Available comparisons offer useful signal.

AWARD-6: The Only Direct Head-to-Head Trial

AWARD-6 was a 26-week, open-label randomized controlled trial comparing dulaglutide 1.5 mg weekly to liraglutide 1.8 mg daily in 599 adults with type 2 diabetes on metformin. Published data from AWARD-6 show that dulaglutide 1.5 mg achieved non-inferiority to liraglutide 1.8 mg for HbA1c reduction (mean change: -1.42% vs. -1.36%, respectively). Both arms reached a mean HbA1c of approximately 6.9% from a baseline near 8.1%. Weight loss was numerically similar, though liraglutide showed a slight edge: -3.61 kg vs. -2.90 kg. The trial's full dataset is indexed on PubMed.

Real-World Glycemic Data

Registry and claims-data studies reinforce the trial findings. A retrospective cohort analysis published in Diabetes, Obesity and Metabolism using US electronic health records found comparable HbA1c reductions between once-weekly GLP-1 agents and liraglutide at 6 and 12 months, with adherence rates favoring weekly regimens. Patients on once-daily liraglutide were more likely to discontinue within the first 90 days, largely due to injection burden and gastrointestinal side effects. That observational cohort data is available via PubMed.

Higher Dulaglutide Doses

The dulaglutide label was updated in 2020 to include 3.0 mg and 4.5 mg weekly doses. The AWARD-11 trial (N=1,842) showed that dulaglutide 4.5 mg reduced HbA1c by 1.77% from baseline and produced 4.7 kg of weight loss at 36 weeks, outperforming the 1.5 mg dose on both endpoints. At 4.5 mg weekly, dulaglutide's glycemic effect moves closer to the weight-loss doses seen with semaglutide, though it still falls short of liraglutide 3.0 mg (Saxenda) for dedicated weight management.

Weight Loss: Where Liraglutide Has a Documented Edge

Weight loss is the one domain where liraglutide holds a clearer clinical advantage, at least when used at the 3.0 mg Saxenda dose.

SCALE Obesity Trial

The SCALE Obesity and Prediabetes trial (N=3,731) tested liraglutide 3.0 mg daily against placebo in adults without diabetes. At 56 weeks, liraglutide 3.0 mg produced a mean weight loss of 8.4 kg (8.0% of body weight) compared with 2.8 kg (2.6%) in the placebo group, a difference of 5.6 kg (P<0.001). Sixty-three percent of liraglutide-treated patients lost at least 5% of body weight versus 27% on placebo. Full SCALE Obesity results are on PubMed.

Dulaglutide's Weight Profile

Dulaglutide at 1.5 mg weekly produces modest weight loss of roughly 1.5 to 3 kg in diabetes trials. At the higher 4.5 mg dose in AWARD-11, weight loss reached 4.7 kg. This is clinically meaningful but does not match the 8+ kg seen with liraglutide 3.0 mg or the 15.9% body-weight reduction shown with semaglutide 2.4 mg in STEP-1 (N=1,961). STEP-1 primary results are indexed at PubMed. For patients whose primary goal is substantial weight reduction, the evidence favors liraglutide 3.0 mg over dulaglutide at any approved dose, though semaglutide 2.4 mg (Wegovy) has largely supplanted both in dedicated obesity management.

Cardiovascular Outcomes: Two Positive Trials, Different Populations

Both drugs have cardiovascular outcome trial (CVOT) evidence, but the trials enrolled meaningfully different populations and measured slightly different endpoints.

LEADER Trial (Liraglutide)

The LEADER trial (N=9,340) tested liraglutide 1.8 mg daily versus placebo in adults with type 2 diabetes and high cardiovascular risk. At a median follow-up of 3.8 years, liraglutide reduced the primary composite MACE endpoint (cardiovascular death, nonfatal MI, nonfatal stroke) by 13% relative to placebo (HR 0.87; 95% CI 0.78 to 0.97; P<0.001 for non-inferiority, P=0.01 for superiority). Cardiovascular death was reduced by 22%. LEADER trial data are on PubMed.

REWIND Trial (Dulaglutide)

The REWIND trial (N=9,901) tested dulaglutide 1.5 mg weekly against placebo. At a median of 5.4 years, dulaglutide reduced the primary MACE composite by 12% (HR 0.88; 95% CI 0.79 to 0.99; P=0.026). Critically, 31% of REWIND participants had no prior cardiovascular disease at enrollment, making it one of the first CVOTs to show cardiovascular benefit in a predominantly primary-prevention population. The REWIND publication is available at The Lancet and indexed on PubMed.

Comparing the Trials

Neither drug's CVOT was designed to be compared directly to the other's. Baseline characteristics differ: LEADER enrolled a higher-risk cohort. REWIND's wider net means dulaglutide's cardiovascular label is arguably more applicable to patients with risk factors but no established disease. The ADA Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, citing both liraglutide and dulaglutide among agents with Level A evidence. ADA Standards of Care 2024 are available via the American Diabetes Association.

Tolerability and Side Effects

Gastrointestinal Profile

Nausea, vomiting, and diarrhea are class effects shared by both drugs. Because liraglutide is dosed daily, plasma concentrations peak more frequently, which may explain the slightly higher GI event rates reported with liraglutide versus dulaglutide in AWARD-6 (26% vs. 21% nausea). A 2021 network meta-analysis of GLP-1 receptor agonists published in Diabetes Care found that once-daily agents generally carried a modestly higher rate of nausea-driven discontinuation compared with once-weekly agents, though absolute differences were small.

Injection Site Reactions

Both drugs carry low rates of injection site reactions (<5% in trials). Dulaglutide's autoinjector conceals the needle entirely, which several patient-preference studies flag as a significant advantage for injection-naive individuals. A prospective study in Diabetes Technology and Therapeutics found greater device satisfaction with needle-hidden autoinjectors compared with standard pen devices in GLP-1-naive adults.

Heart Rate Increase

Both drugs raise resting heart rate by approximately 1 to 3 beats per minute. This is a class effect and has not been linked to increased arrhythmia risk in either LEADER or REWIND, though clinicians typically monitor pulse in patients with baseline tachycardia. A summary of GLP-1 cardiovascular effects appears in a 2019 review in the New England Journal of Medicine.

Pancreatitis and Thyroid C-Cell Risk

Both carry FDA label warnings for pancreatitis and, in animal models, thyroid C-cell tumors. Neither has demonstrated a statistically significant increase in medullary thyroid carcinoma in humans, but both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2. The FDA prescribing guidance for liraglutide summarizes this contraindication.

Real-World Adherence and Persistence

Adherence data consistently favor once-weekly agents. A retrospective analysis of pharmacy claims from a large US health plan published in the Journal of Managed Care and Specialty Pharmacy found 12-month medication possession ratios of 0.72 for once-weekly GLP-1 agents versus 0.61 for once-daily liraglutide. Patients who remained adherent to either drug achieved broadly similar HbA1c reductions, reinforcing that the clinical outcome gap between these two agents may be largely adherence-mediated rather than pharmacodynamic. That adherence analysis is indexed on PubMed.

Injection frequency is not the only adherence driver. Cost matters too. Generic liraglutide entered the US market in 2024, and compound pharmacy liraglutide has been widely prescribed for weight management purposes. Dulaglutide (Trulicity) does not yet have a generic equivalent, and its branded list price exceeds $800 per month without insurance. For patients paying out of pocket, generic liraglutide may be substantially more affordable, and this cost differential could reverse the adherence advantage normally attributed to weekly dosing.

Dosing and Titration Protocols

Liraglutide Titration

For type 2 diabetes (Victoza), the starting dose is 0.6 mg subcutaneously once daily for 1 week, then 1.2 mg daily, with an optional increase to 1.8 mg daily for additional glycemic control. For weight management (Saxenda), titration is slower: 0.6 mg daily in week 1, increasing by 0.6 mg each week until reaching 3.0 mg daily by week 5. Full titration guidance appears in the FDA-approved Saxenda label.

Dulaglutide Titration

The starting dose is 0.75 mg subcutaneously once weekly for at least 4 weeks, then 1.5 mg weekly. If additional glycemic control is needed, doses may increase to 3.0 mg and then 4.5 mg weekly at 4-week intervals. The 4-week escalation interval is longer than liraglutide's 1-week step, which may result in a slower onset of meaningful glycemic effect. The full dulaglutide prescribing information is on the FDA website.

Switching from Liraglutide to Trulicity: Clinical Guidance

Switching between GLP-1 receptor agonists is clinically common, driven by tolerability issues, cost changes, patient preference for weekly dosing, or formulary changes. There is no universally agreed washout period required between agents, given their shared mechanism and generally additive GI side-effect profile.

When Switching Makes Sense

A switch from liraglutide to dulaglutide is reasonable in these scenarios:

• The patient finds daily injection burdensome and adherence is suffering.
• Gastrointestinal side effects are bothersome on liraglutide and a slower titration schedule may help.
• The primary goal is cardiovascular risk reduction in a patient with risk factors but no established cardiovascular disease (per REWIND's broader enrollment criteria).
• The patient is injection-naive and would benefit from Trulicity's concealed-needle autoinjector.

When Staying on Liraglutide (or Switching to a Higher-Efficacy Agent) Makes More Sense

Liraglutide, particularly at the 3.0 mg Saxenda dose, remains the better-evidenced option for patients whose primary goal is clinically meaningful weight loss. If a patient on liraglutide 1.8 mg is not achieving weight goals, escalating to Saxenda 3.0 mg is a logical next step before switching drug classes. If weight loss goals remain unmet at Saxenda 3.0 mg, semaglutide 2.4 mg (Wegovy) offers substantially greater efficacy: STEP-1 demonstrated 14.9% mean body weight reduction at 68 weeks versus 2.4% on placebo. STEP-1 full results are on PubMed.

Practical Transition Steps

When converting from daily liraglutide to weekly dulaglutide, most clinicians start dulaglutide at 0.75 mg weekly with no mandatory washout. The last liraglutide injection is given on day 1; dulaglutide begins on day 2 or any convenient weekly day. Because GI side effects may temporarily worsen during the transition period as the gut adjusts to a different molecule and dosing pattern, patients should be counseled to take dulaglutide with a meal during the first few weeks. The American Association of Clinical Endocrinology (AACE) Comprehensive Diabetes Management Algorithm advises titrating GLP-1 agents slowly to minimize GI side effects at initiation or reinitiation.

Cost and Access

Generic liraglutide became available in the United States in 2024. Branded Victoza list price has historically exceeded $700 per month, but compounded and generic versions are available at significantly lower cost through many pharmacies. Trulicity (dulaglutide) carries a branded list price of approximately $820, $900 per month; no generic is currently approved. Eli Lilly offers the Trulicity Savings Card for commercially insured patients, potentially reducing copays to $25, $35 per month, though this program excludes Medicare and Medicaid beneficiaries. Patients on Medicare Part D should verify their plan formulary, as tier placement varies. FDA guidance on biosimilars and generic small-molecule drugs is available at FDA.gov.

Summary Comparison Table

| Feature | Liraglutide | Dulaglutide (Trulicity) | |---|---|---| | Injection frequency | Once daily | Once weekly | | Starting dose | 0.6 mg/day | 0.75 mg/week | | Max approved dose (T2D) | 1.8 mg/day | 4.5 mg/week | | Weight loss (T2D doses) | 2 to 4 kg | 1.5 to 3 kg | | Weight loss (obesity dose) | 8.4 kg (3.0 mg, SCALE) | Not approved for obesity | | HbA1c reduction (head-to-head) | -1.36% (AWARD-6) | -1.42% (AWARD-6) | | CVOT trial | LEADER | REWIND | | Established ASCVD required | Yes (LEADER) | No (REWIND includes primary prevention) | | FDA obesity indication | Yes (Saxenda 3.0 mg) | No | | Generic available | Yes (2024) | No | | Device | Prefilled pen | Concealed-needle autoinjector |